← Back to Search

Imaging Device

Optical coherence tomography angiography for Diabetic Retinopathy

N/A

Waitlist Available

Research Sponsored by University of British Columbia

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 18 months

Awards & highlights

Study Summary

This trial will compare retinas of patients with diabetes to healthy controls, in order to evaluate micro-vascular changes in diabetes.

Eligible Conditions

Diabetic Retinopathy
Diabetes

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 18 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~18 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 18 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Perfusion density

Secondary outcome measures

Areas of different perfusion density

Change in perfusion density in patients with moderate or severe non proliferative diabetic retinopathy (DR) or low risk proliferative DR over the follow up of one year

Foveal avascular zone (FAZ)

+2 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: OCTAExperimental Treatment1 Intervention

Patients with diabetes and healthy controls will be imaged with optical coherence tomography (OCT) angiography, Spectral domain OCT and ultra wide-field imaging.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Optical coherence tomography angiography

2017

N/A

~420

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of British ColumbiaLead Sponsor

1,419 Previous Clinical Trials

2,466,993 Total Patients Enrolled

4 Trials studying Diabetic Retinopathy

38 Patients Enrolled for Diabetic Retinopathy

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the current enrollment number of participants taking part in this trial?

"Indeed, the clinicaltrials.gov portal confirms that recruitment is ongoing for this medical experiment, which was initially published on September 20th 2018 and updated lastly on September 29th 2021. The investigation calls for 175 participants to be enrolled at a single location."

Answered by AI

Are there any unfilled spots in this clinical trial available to participants?

"Per the details on clinicaltrials.gov, this medical trial is seeking participants and has been doing so since September 20th 2018. The study was last edited on September 29th 2021."

Answered by AI

Recent research and studies

Investigative Opthalmology & Visual ScienceJournal

Evaluating Signs of Microangiopathy Secondary to Diabetes in Different Areas of the Retina with Swept Source OCTA

Karst, Sonja G., Morgan Heisler, Julian Lo, Nathan Schuck, Abdollah Safari, Marinko V. Sarunic, David A. L. Maberley, and Eduardo V. Navajas. 2020. “Evaluating Signs of Microangiopathy Secondary to Diabetes in Different Areas of the Retina with Swept Source OCTA”. Investigative Opthalmology & Visual Science. Association for Research in Vision and Ophthalmology (ARVO). doi:10.1167/iovs.61.5.8.

clinicaltrials.govStudy

Macular Involvement in Diabetic Retinopathy Evaluated With Swept-Source OCT

Eduardo Navajas 2018. "Macular Involvement in Diabetic Retinopathy Evaluated With Swept-Source OCT". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03765112.

All > Diabetic Retinopathy